Importantly, aberrant STAT3 signalling through pathways such as VEGFA not only drives tumour growth but also contributes to drug resistance by promoting a tumour-supportive microenvironment, enhancing cancer cell survival, and impairing therapeutic efficacy. Here, STAT3 is linked to neoplasm.